Microdosing of GLP-1's The Rationale for Microdosing While GLP-1 receptor agonists (GLP-1 RAs) are effective treatments, higher doses can cause gastrointestinal side effects such as nausea and vomiting
Exendin-4 treatment for 812 weeks also reduced atherosclerosis (7, 8) and plaque macrophages (8) in Ldlr / mice on a high-cholesterol diet (HCD) (6)
If morning dosing does not work with your schedule, evening dosing is an acceptable alternative
As of 2021, use of GLP-1 medications has surged, with many users taking them for weight loss rather than type 2 diabetes management
Private label partners who establish early presence in this category are positioned to benefit from long-term demand growth and evolving consumer adoption
Some GLP-1 receptor agonists are approved for patients with an eGFR as low as 15 mL/min/1.73 m, but professional guidance is key